BioInvent and Servier enter Oncology collaboration

BioInvent International AB (Bioinvent) and Les Laboratoires Servier (Servier) have entered into an antibody collaboration on an oncology target involved in tumour cell metabolism provided by Servier. BioInvent will receive a licensing fee, research support and potential milestone payments of more than EUR 11m, as well as royalty on future sales of the product.

Svein Mathisen, President and CEO of BioInvent, said: “We believe Servier is an excellent partner for this research project in antibody discovery and research. Oncology is a prioritized area for BioInvent as for Servier and we look forward to joining our knowledge to theirs in this area.”

BioInvent is a research-based pharmaceutical company developing innovative antibody drugs to target diseases with unmet clinical need. The company employs around 100 people and is based in Lund, Sweden. The Company was listed on the NASDAQ OMX Stockholm in 2001.

Posted at Thu, 01/12/2012 - 13:33

Comments 0

BioInvent and Servier enter Oncology collaboration

Search

Events

News